Image via Wikipedia
Stem cell researchers have a lot of big dreams, and one is to someday regenerate damaged hearts. That is still many years away from becoming a commercial reality, if ever, but a few University of Washington scientists have formed a new company that hopes to make cells that can replace pacemakers, and someday rebuild damaged heart tissue that people are left with after heart attacks.
The company, Bellevue, WA-based Beat BioTherapeutics, is the brainchild of Chuck Murry and Michael Laflamme, a pair of UW stem cell researchers, and UW bioengineering professor Buddy Ratner. It has roots in about
The study Sun has been working on in Dr. Farshid Guilak’s laboratory has found that engineered cartilage constructed from a particular type of stem cell integrate well with host cartilage, but not necessarily in a uniform way.
Sun was one of about thirty biomedical engineering students who presented at the department’s graduation with distinction reception on April 26. Other students have been working on exciting projects in optic imaging of tumors, synthetic biology, and deep brain stimulation, among other topics.
Sun’s project focused on how induced pluripotent stem cells can be used to study cartilage regeneration and repair.
University of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer.
To prove the cells’ regenerative powers, bone cells grown on this surface were then transplanted into holes in the skulls of mice, producing four times as much new bone growth as in the mice without the extra bone cells.
An embryo’s cells really can be anything they want to be when they grow up: organs, nerves, skin, bone, any type of human cell. Adult-derived “induced” stem
From a simple blood draw, Krishanu Saha, a researcher in WID’s BIONATES research group and assistant professor of biomedical engineering, could enable doctors to create stem cells to develop drugs personalized to their patients.
As part of his $400,000 National Science Foundation CAREER Award over the next five years, Saha will focus on improving the process to directly evolve DNA sequences and proteins in human stem cells.
Stem cells have the potential to develop into many different cell types, which makes them ideal for a variety of medical research projects.
The evolution of synthetic DNA sequences in human stem cells could catalyze
Stem cells – unspecialized cells that have the potential to develop into different types of cells – play an important role in medical research. In the embryotic stage of an organism’s growth, stem cells develop into specialized heart, lung, and skin cells, among others; in adults, they can act as repairmen, replacing cells that have been damaged by injury, disease, or simply by age.
Given their enormous potential in future treatments against disease, the study and growth of stem cells in the lab is widespread and critical. But growing the cells in culture offers numerous challenges, including the constant need